For Merck, the drug that concerns investors is Keytruda. The blockbuster cancer drug faces patent expiration in 2028.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback